A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects

Trial Profile

A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2012

At a glance

  • Drugs Esomeprazole/naproxen (Primary)
  • Indications Ankylosing spondylitis; Osteoarthritis; Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Jun 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 21 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top